共 85 条
[21]
Park SH(2007)Docetaxel-cisplatin-5FU (TCF) versus docetaxel-cisplatin (TC) versus epirubicin-cisplatin-5FU (ECF) as systemic treatment for advanced gastric carcinoma (AGC): a randomized phase II trial of the Swiss Group for Clinical Cancer Research (SAKK) J Clin Oncol 25 3217-3319
[22]
Hohenberger P(2003)Cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) is more active than 5-fluorouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinoma Ann Oncol 14 1258-1502
[23]
Gretschel S(1994)Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. North Central Cancer Treatment Group J Clin Oncol 12 412-269
[24]
Kim T(1997)Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin, glutathione, and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer J Clin Oncol 15 3313-80
[25]
Choi SJ(2005)Epirubicin, cisplatin and docetaxel combination therapy for metastatic gastric cancer Ann Oncol 16 1498-undefined
[26]
Ahn JH(2006)Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG Ann Oncol 17 262-undefined
[27]
Van Cutsem E(2008)Bimonthly 24 h infusion of high-dose 5-fluorouracil vs EAP regimen in patients with advanced gastric cancer. A randomized phase II study Med Oncol 25 73-undefined
[28]
Moiseyenko VM(undefined)undefined undefined undefined undefined-undefined
[29]
Tjulandin S(undefined)undefined undefined undefined undefined-undefined
[30]
Park YS(undefined)undefined undefined undefined undefined-undefined